BTW, I see that GSK has another Lp-PLA2 inhibitor from the same family as darapladib (also from HGS), completed phase II in atherosclerosis and active in AD. http://www.gsk-clinicalstudyregister.com/protocol_detail.jsp?protocolId=LP2105521&studyId=7D1AFC17-B7CE-4B6E-9179-DFF5E8FA1163&compound=rilapladib